Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • rammohanshukla
    Junior Member
    • Mar 2013
    • 4

    #1

    Deseq2 design clarification

    Hi, I am working with human postmortem samples wherein I have 5 groups of subjects:

    A. Control: 20 samples
    B. First episode: 20 samples
    C. First episode Remission: 15 samples
    D. Second episode: 20 samples
    E. Second episode Remission: 15 samples


    Note that the progression of A to B to C to D to E is expected to be in phase (something like sinusoidal curve)

    I also have other parameters for the samples, which include: Age, Sex, RIN value, PMI (postmortem interval), pH of the sample


    I wish to test the difference of the 5 groups in ANOVA like analysis in DEseq2 but after controlling for Age, Sex, RIN value, PMI (postmortem interval), pH of the sample

    My phenotype table looks like this:

    Sample Age Sex Rin PMI pH DiseaseStage
    1 binned factor binned binned binned Control
    2 Control
    3 First episode
    . First episode
    . First episode
    . .
    . .
    90 Second episode Remission



    This is my design
    dds <- DESeqDataSet(se, design = ~ Age+Sex+RIN+PMI+pH+DiseaseStage)

    dds <- DESeq(dds, test = "LRT", reduced = ~ Age+Sex+RIN+PMI+pH)
    results(dds)

    I am hoping that I get 1 p-value for ANOVA like comparisons between the disease stage after controlling for Age, Sex, RIN, PMI and pH
    Also, I would like to know how many variables I can control for in the design? For instance, here I am using 5 (Age, Sex, RIN, PMI and pH) is it okay? If yes, is there any rule to how many variables to control for in the design?

Latest Articles

Collapse

  • SEQadmin2
    Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
    by SEQadmin2



    CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

    Despite this, “CRISPR helped turn genome editing from a specialized technique into
    ...
    07-31-2026, 11:01 AM
  • SEQadmin2
    Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
    by SEQadmin2


    Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

    The systematic characterization of the human proteome has
    ...
    07-20-2026, 11:48 AM
  • SEQadmin2
    Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
    by SEQadmin2



    Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
    ...
    07-09-2026, 11:10 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, Yesterday, 10:13 AM
0 responses
14 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-31-2026, 02:55 AM
0 responses
28 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-24-2026, 12:17 PM
0 responses
21 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-23-2026, 11:41 AM
0 responses
21 views
0 reactions
Last Post SEQadmin2  
Working...